Shannon N. Westin

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-1922-0156

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.4Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3

Top 8%

2.7DataRank

Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Papers

Driven by 65 papers — median percentile 81. Top paper: “Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer”.

Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer

American Journal of Obstetrics and Gynecology(2020)10.1016/j.ajog.2020.08.032

N/A

4.0DataRank · unranked

125 citations

Bryan Fellman, Charlotte C. Sun, Russell R. Broaddus, Misty Woodall, Navdeep Pal +14 more

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Cell Reports(2020)10.1016/j.celrep.2020.03.066

N/A

2.9DataRank · unranked

143 citations

Li Zhao, Christine Rojas, Nicholas W. Bateman, Hui Yao, Olivia D. Lara +41 more

Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Nature Communications(2021)10.1038/s41467-021-25177-3

Top 8%

2.7DataRank

Top 8%109 citations

Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl +94 more

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.682

N/A

2.3DataRank · unranked

71 citations

Shannon N. Westin, Gloria Salvo, Abdulrazzak Zarifa, Mingxuan Xu, Timothy A. Yap +6 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Investigational New Drugs(2021)10.1007/s10637-020-01043-9

N/A

1.1DataRank · unranked

25 citations

Amir A. Jazaeri, Shannon N. Westin, Anil K. Sood, Lois M. Ramondetta, Mingxuan Xu +8 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

NAR Cancer(2022)10.1093/narcan/zcac014

Top 31%

0.652DataRank

Top 31%22 citations

Michael W. Lloyd, Jeffrey W. Grover, Nan Xiao, Sara Seepo, Sai Lakshmi Subramanian +95 more

The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.498

N/A

0.598DataRank · unranked

53 citations

Charlotte C. Sun, Revathy B. Iyer, Alpa M. Nick, Nicole D. Fleming, Shannon N. Westin +5 more

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

British Journal of Cancer(2021)10.1038/s41416-020-01230-8

N/A

0.568DataRank · unranked

43 citations

Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb +10 more

PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101326

N/A

0.510DataRank · unranked

29 citations

Lacey E. Dobrolecki, Christina Sallas, Xudong Zhang, Travis Kerr, Deepa Bisht +19 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0.416DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0362

N/A

0.312DataRank · unranked

7 citations

Brenda Melendez, Qian Zhang, Richard K. Yang, Bryan Fellman, Barrett C. Lawson +11 more

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

Med(2024)10.1016/j.medj.2024.07.022

N/A

0.299DataRank · unranked

4 citations

Minghao Dang, Sanghoon Lee, Bryan Fellman, Shannon N. Westin, Anil K. Sood +19 more

EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5573

N/A

0.104DataRank · unranked

1 citations

Emily Hinchcliff, Shuqi Wang, Amir A. Jazaeri, Anil K. Sood, Bryan Fellman +14 more

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

Nature Cancer(2022)10.1038/s43018-022-00438-2

N/A

0DataRank · unranked

37 citations

Mei‐Kuang Chen, Yongkun Wei, Heng‐Huan Lee, Weiya Xia, Ying‐Nai Wang +21 more

State of the science: Contemporary front-line treatment of advanced ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.021

N/A

0DataRank · unranked

28 citations

Shannon N. Westin, Thomas J. Herzog, Emily Hinchcliff

Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.009

N/A

0DataRank · unranked

18 citations

Anil K. Sood, Graziela Zibetti Dal Molin, Shannon N. Westin, Larissa A. Meyer, Bryan Fellman +4 more

Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer

Journal of Cancer Research and Clinical Oncology(2022)10.1007/s00432-021-03885-z

N/A

0DataRank · unranked

16 citations

Nicholas B. Jennings, Yunjie Sun, Santosh K. Dasari, Emine Bayraktar, Sara Corvigno +8 more

Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.005

N/A

0DataRank · unranked

16 citations

Lauren Cobb, Shannon N. Westin, Yingao Zhang, Amir A. Jazaeri, Anaís Malpica +2 more

Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.025

N/A

0DataRank · unranked

12 citations

Silvana Pedra Nobre, Bryan Fellman, David A. Iglesias, Kristina Lindemann, Anuja Jhingran +7 more

Targeting the PI3K Pathway in Gynecologic Malignancies

Current Oncology Reports(2022)10.1007/s11912-022-01326-9

N/A

0DataRank · unranked

12 citations

Michaela Onstad Grinsfelder, Melissa Pham, Shannon N. Westin, Monica Avila

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.004

N/A

0DataRank · unranked

8 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +16 more

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

The Oncologist(2023)10.1093/oncolo/oyad085

N/A

0DataRank · unranked

28 citations

Amir A. Jazaeri, Shannon N. Westin, Curtis A. Pettaway, Solly George, Ryan Huey +8 more

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

Cancer(2023)10.1002/cncr.35126

N/A

0DataRank · unranked

18 citations

Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan, Ami Patel +16 more

Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors

American Journal of Obstetrics and Gynecology(2023)10.1016/j.ajog.2023.02.029

N/A

0DataRank · unranked

17 citations

Alejandra Flores Legarreta, Rhea Kamat, Katelyn F. Handley, Deanna Glassman, Jeffrey How +8 more

Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer

International Journal of Molecular Sciences(2023)10.3390/ijms24043915

N/A

0DataRank · unranked

11 citations

Robiya Joseph, Sujanitha Umamaheswaran, Lingegowda S. Mangala, Emine Bayraktar, Cristian Rodriguez‐Aguayo +12 more

Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer

Cancer(2023)10.1002/cncr.34724

N/A

0DataRank · unranked

9 citations

Kenna Shaw, Fengyi Jin, Shannon N. Westin, Timothy A. Yap, Deanna Glassman +9 more

Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer

Endocrinology(2023)10.1210/endocr/bqad071

N/A

0DataRank · unranked

7 citations

Eleonora Dondossola, Kaitlin J. Basham, Nathaniel R. Wilson, Omar Alhalabi, Jianjun Gao +7 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5533

N/A

0DataRank · unranked

1 citations

Rebecca Paulus, Ann H. Klopp, Lari Wenzel, Anamaria R. Yeung, J. S. Thompson +15 more

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5629

N/A

0DataRank · unranked

1 citations

David Bender, Danielle Enserro, Shannon N. Westin, Debra L. Richardson, Laura L. Holman +10 more

Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

(2023)10.1158/1535-7163.c.6543538

N/A

0DataRank · unranked

0 citations

Cristian Rodriguez‐Aguayo, Shaolin Ma, Elaine Stur, Robiya Joseph, Emine Bayraktar +17 more

Translating biological insights into improved management of endometrial cancer

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00934-7

N/A

0DataRank · unranked

32 citations

Amir A. Jazaeri, Shannon N. Westin, Barrett C. Lawson, Ann H. Klopp, Pamela T. Soliman +2 more

Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors

American Journal of Obstetrics and Gynecology(2024)10.1016/j.ajog.2024.01.002

N/A

0DataRank · unranked

14 citations

Alejandra Flores Legarreta, Katelyn F. Handley, Bryan Fellman, Katherine Foster, Deanna Glassman +10 more

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2819

N/A

0DataRank · unranked

12 citations

Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo +19 more

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer

Current Oncology Reports(2024)10.1007/s11912-024-01603-9

N/A

0DataRank · unranked

5 citations

Mikayla B. Bowen, Roni Nitecki Wilke, Melinda S. Yates, Shannon N. Westin, Naomi Adjei

EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

International Journal of Molecular Sciences(2024)10.3390/ijms25021278

N/A

0DataRank · unranked

8 citations

Santosh K. Dasari, Sujanitha Umamaheswaran, Lingegowda S. Mangala, Emine Bayraktar, Cristian Rodriguez‐Aguayo +17 more

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

iScience(2024)10.1016/j.isci.2024.109801

N/A

0DataRank · unranked

5 citations

Emily Hinchcliff, Elisabeth Gardiner, Reshma Rangwala, Kathryn Lito, Bryan Fellman +6 more

The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005893

N/A

0DataRank · unranked

2 citations

Jinsong Liu, Shannon N. Westin, Bryan Fellman, Travis T. Sims, Melissa Pham +7 more

Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.tps5626

N/A

0DataRank · unranked

9 citations

Hind Rafei, Rafet Başar, Pinaki P. Banerjee, Zeyad Metwalli, Kathryn Lito +13 more

Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5573

N/A

0DataRank · unranked

1 citations

Charles A. Wolfe, Michael F. Keating, Marta Sans, Kelly M. Rangel, Calvin Sunny +10 more

PPP2R1A mutations portend improved survival after cancer immunotherapy

Nature(2025)10.1038/s41586-025-09203-8

N/A

0DataRank · unranked

29 citations

Anne Knisely, Mitsutake Yano, Minghao Dang, Emily Hinchcliff, Sanghoon Lee +36 more

A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy

Scientific Reports(2025)10.1038/s41598-025-98434-w

N/A

0DataRank · unranked

9 citations

Yu‐Chun Hsu, Amma Asare, Kai Zhang, Deanna Glassman, Katelyn F. Handley +10 more

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.02.015

N/A

0DataRank · unranked

2 citations

Rebecca A. Previs, Daniel Spinosa, Bryan Fellman, Amelia L. Scott, Isabelle Mulder +10 more

EphA2 siRNA in DOPC nanoliposomes (EPHARNA): A phase I clinical trial in patients with solid tumors.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3086

N/A

0DataRank · unranked

0 citations

Aung Naing, Gabriel Lopez‐Berestein, Cristian Rodríguez-Aguayo, Hassan Ahmed Momin, Anupama Madhyannapu +11 more

Fertility-Sparing Practices in Uterine Malignancies: A Literature Review

Journal of Gynecologic Surgery(2025)10.1177/10424067251384464

N/A

0DataRank · unranked

0 citations

Roni Nitecki Wilke, Pamela T. Soliman, Shannon N. Westin, Jeffrey How, Ravali A. Reddy

First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma

medRxiv(2025)10.1101/2025.11.07.25339137

N/A

0DataRank · unranked

0 citations

Samira Aghlara-Fotovat, Jake Schladenhauffen, Jonathon DeBonis, Juan Carlos Amador-Molina, Amanda Nash +24 more

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

The Oncologist(2025)10.1093/oncolo/oyaf413

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Emily Thompson, R. Jason Stafford, Hung Le, Lei Kang +12 more

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Journal of Clinical Oncology(2020)10.1200/jco.20.01924

N/A

0DataRank · unranked

315 citations

Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman +11 more

PARP inhibition in the ovarian cancer patient: Current approvals and future directions

Pharmacology & Therapeutics(2020)10.1016/j.pharmthera.2020.107588

N/A

0DataRank · unranked

16 citations

Monica Avila, Emily Hinchcliff, Robert L. Coleman, Shannon N. Westin, Katherine C. Kurnit

Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer

International Journal of Gynecological Cancer(2020)10.1136/ijgc-2020-001718

N/A

0DataRank · unranked

8 citations

Shannon N. Westin, Larissa A. Meyer, Aaron Shafer, Jose Alejandro Rauh‐Hain, Michaela Onstad +12 more

Pushing the envelope: expanding fertility sparing treatment of endometrial cancer

Journal of Gynecologic Oncology(2020)10.3802/jgo.2020.31.e82

N/A

0DataRank · unranked

5 citations

Melinda S. Yates, Shannon N. Westin, Katherine Stewart

An Integrated Approach to Selecting a Prepared Medical Decision-Maker

Journal of Pain and Symptom Management(2020)10.1016/j.jpainsymman.2020.12.006

N/A

0DataRank · unranked

2 citations

Ali Haider, Janet L. Williams, Syed Naqvi, Neeraj Joshi, Sarah Mills +13 more

Has dose-dense chemotherapy met an ICONic end?

The Lancet Oncology(2020)10.1016/s1470-2045(20)30276-x

N/A

0DataRank · unranked

1 citations

Larissa A. Meyer, Shannon N. Westin, Emily Hinchcliff

Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer

International Journal of Gynecological Cancer(2020)10.1136/ijgc-2020-001597

N/A

0DataRank · unranked

1 citations

Rebecca A. Previs, Bryan Fellman, Tarrik M. Zaid, Marilyn Huang, Alaina J. Brown +10 more

Incidence of trocar site herniation following robotic gynecologic surgery

UNC Libraries(2020)10.17615/ehf0-4302

N/A

0DataRank · unranked

0 citations

Nicole D. Fleming, Leslie H. Clark, Shannon N. Westin, Diego Odetto, Pedro T. Ramírez +4 more

Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.04.034

N/A

0DataRank · unranked

54 citations

Shrina Patel, Bryan Fellman, Karen H. Lu, Patrick Hwu, Lois M. Ramondetta +5 more

Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status

Journal of Cancer Research and Clinical Oncology(2021)10.1007/s00432-021-03778-1

N/A

0DataRank · unranked

10 citations

Jared K. Burks, Wei Hu, Yanping Zhong, Nicholas B. Jennings, Nicole D. Fleming +5 more

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5505

N/A

0DataRank · unranked

83 citations

Robert L. Coleman, Bryan Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman +15 more

Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5568

N/A

0DataRank · unranked

5 citations

Anil K. Sood, Shannon N. Westin, Bryan Fellman, Jenna Unke, Kelly M. Rangel +3 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Futility and toxicity monitoring without halting for interim analyses.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e13579

N/A

0DataRank · unranked

0 citations

Shannon N. Westin, Ying Yuan, Diana L. Urbauer

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5565

N/A

0DataRank · unranked

0 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +15 more

Shannon N. Westin

Indexed papers

Top data-sharing exemplar

Papers